Triazolam

DRUG6 trials

Sponsors

Pfizer, Janssen Research & Development, LLC, Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Hannover Medical School, Akili Interactive Labs, Inc.

Conditions

Anxiety DisordersDementiaDepressionHealthyHealthy VolunteersPsychosomatic DisordersSchizophreniaSedation

Phase 1

Triazolam Trial In Healthy Subjects To Compare Bioavailability Between Formulations Of Triazolam To Determine Their Bioequivalence In Terms Of Rate And Magnitude Of Absorption

WithdrawnNCT01017926

PfizerHealthy Volunteers

Start: 2010-08-31End: 2010-09-30Updated: 2016-04-06

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants

CompletedNCT01780259

Janssen Research & Development, LLCHealthy

Start: 2012-12-31End: 2013-05-31Updated: 2013-08-09

Phase 3

Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers

CompletedNCT01888497

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Healthy

Start: 2013-07-29End: 2013-12-14Updated: 2021-02-21

Pharmacovigilance in Gerontopsychiatric Patients

TerminatedNCT02374567

Hannover Medical SchoolAnxiety Disorders, Dementia, Depression +2

Start: 2015-01-31End: 2017-06-28Updated: 2018-02-28

Phase 4

Oral Versus Intravenous Sedation for Ocular Procedures

CompletedNCT03246724

Boston Medical CenterSedation, Surgery

Start: 2017-10-16End: 2019-11-30Updated: 2020-08-19

Unknown Phase

Sensitivity of Project: EVO Monitor Cognitive Measurements to Pharmacological Agents

CompletedNCT02822937

Akili Interactive Labs, Inc.Healthy

Start: 2016-07-31End: 2016-11-30Updated: 2016-11-07

Related Papers

Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression.

2020-10-3134 citations